Lineage Cell Therapeutics Inc
LCTX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$248.73M
Close$
$-1.33
233.6% downside
Current Fair Value
233.6% downsideOvervalued by 233.6% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $248.73 Million |
|---|---|
| Enterprise Value | $215.35 Million |
| Earnings per Share | $-0.28 |
| Beta | 1.6 |
| Outstanding Shares | 249,499,000 |
Return
| Return on Equity | -53.95% |
|---|---|
| Return on Assets | -30.37% |
| Return on Invested Capital | -16.68% |
Valuation & Multiples
| P/E Ratio | -7.13 |
|---|---|
| PEG | 6.8 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 16.46 |
| Enterprise Value to EBIT | -13.14 |
| Enterprise Value to Net Income | -7 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.07 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.03
Consensus analyst estimateRevenue Estimate
$1.84 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.02
Consensus analyst estimateRevenue Estimate
$2.32 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 20.23% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 3.19%▼ 43.83% |
|---|---|
| Total Invested | $7.61M▼ 95.05% |
| Investors Holding | 26▼ 110.00% |
About Lineage Cell Therapeutics Inc
75 employees
CEO: Brian Culley
Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecti...